The Fly reports that in a research note sent to clients and investors on Thursday, Raymond James research analysts increased their price objective for Boston Scientific (NYSE:BSX) from $48.00 to $54.00. The potential growth in the stock price of the company is 18.34%, according to Raymond James’ target price.
Numerous further reports about BSX have been made. Piper Sandler raised their price target on Boston Scientific shares from $47.00 to $50.00 in a research report released on Friday, September 9th, and gave the stock an “overweight” rating. In a research note released on Tuesday, October 11, Morgan Stanley upgraded the stock of Boston Scientific from “underweight” to “overweight” and raised their price objective for the stock from $49.00 to $50.00. Jefferies Financial Group began investigating Boston Scientific’s stock on Wednesday, October 12. They gave the company a “buy” rating with a $50 price objective. Canaccord Genuity Group raised their price target on Boston Scientific shares from $45.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, October 28th. StockNews.com officially started covering Boston Scientific shares on Wednesday, October 12. They gave the company a “hold” rating. The stock has received a buy recommendation from twelve equity research analysts, a hold recommendation from thirteen, and a strong buy recommendation from one analyst. According to information from Bloomberg.com, the stock currently has an average rating of “Moderate Buy” with a consensus price target of $48.07.
Shares of NYSE:BSX began trading at $45.63 on Thursday. Both the company’s quick ratio and current ratio are 1.45. Its debt to equity is 0.49, its quick ratio is 0.95, its current ratio is 1.45, and its debt to equity is 0.49. The company has a $65.36 billion market value, a P/E ratio of 108.65, a PEG ratio of 2.52, and a beta of 0.85. Shares of the company have a 52-week low of $34.98 and a high of $47.49; their respective 50-day and 200-day moving averages are $42.18 and $40.48.
Boston Scientific (NYSE:BSX) published its most recent quarterly results report on October 26th. The medical device manufacturer’s $0.43 earnings per share (EPS) for the quarter fell short of analysts’ $0.44 forecast by $0.01. Boston Scientific achieved a 14.55 percent return on equity and a net margin of 5.19%. Analysts expected the corporation to earn $3.14 billion in sales during the quarter; nevertheless, $3.17 billion was actually made. In the same period last year, the company’s profits per share came to $0.41. Boston Scientific’s revenue climbed by 8.1% over the previous year. Research analysts predict that Boston Scientific will generate $1.73 in earnings per share for the current year.
In addition, EVP Wendy Carruthers sold 1,678 shares of company stock on November 15. The shares were sold at an average price of $42.60, for a total transaction value of $71,482.80. Following the completion of the sale, the executive vice president will directly own 94,913 company shares, valued at about $4,043,293.80. You can access the Securities and Exchange Commission filing where the sale was disclosed by clicking this link. EVP Eric Francis Yves Thepaut sold 14,952 shares of Boston Scientific stock on November 18. The shares sold for a total of $638,749, or an average cost of $42.72 per share. Currently, the executive vice president is the owner of 57,534 shares of the firm, valued at about $2,457,852.48. You can access a document with details on the transaction that was disclosed to the Securities and Exchange Commission by clicking on this link. EVP Wendy Carruthers additionally sold 1,678 shares of Boston Scientific stock on November 15. The shares were sold at an average price of $42.60, for a total transaction value of $71,482.80. Following the acquisition, the executive vice president now owns 94,913 shares of the firm, valued at a total of $4,043,293.80. The disclosure for this sale is available here. Insiders sold 307,302 shares of company stock for a total of $12,606,784 over the previous ninety days. Insiders of the business own 0.71% of the shares.
Recently, the proportion of BSX shares held by hedge funds and institutional investors changed. Newport Trust Co. boosted its ownership of Boston Scientific by 5,082.5% during the second quarter. Newport Trust Co now owns 7,401,817 shares of the $275,866,000 market cap company after purchasing an additional 7,258,993 shares in the most recent quarter.Boston Scientific’s holdings of DZ Bank AG, Deutsche Zentral Genossenschafts Bank Frankfurt am Main, climbed by 24.5% during the second quarter. DZ Bank AG, Deutsche Zentral Genossenschafts Bank Frankfurt am Main, now owns 20,806,144 shares of the $775,455,000 market cap company after acquiring an additional 4,088,589 shares in the most recent quarter. Lazard Asset Management LLC grew its ownership of Boston Scientific by 23.6% during the second quarter. In comparison to three months ago, Lazard Asset Management LLC currently holds 2,416,974 more shares of the company with a $471,578,000 market capitalization. Arrowstreet Capital Limited Partnership grew its ownership of Boston Scientific by 65.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 5,430,814 shares of the medical equipment provider’s stock valued at $240,531,000 after acquiring an additional 2,157,849 shares in the last recent quarter. Not to mention, Impax Asset Management Group plc boosted its Boston Scientific shares by 47.5% in the third quarter. Compared to three months ago, Impax Asset Management Group plc now owns 2,132,468 more shares of the $255,836,000 market cap company’s stock. Institutional investors and hedge funds hold 90.33% of the company’s stock.
The Boston Scientific Corporation designs, manufactures, and distributes items that are used across a variety of interventional medical fields. The MedSurg, Rhythm and Neuro, and Cardiovascular components are what make it work. The company sells pacemakers, implantable cardiac resynchronization therapy pacemakers, implantable cardioverter-defibrillators, and devices to diagnose and treat gastrointestinal, lung, and different urological and pelvic disorders.
